Poster 539-P. ADA funded research; Use of pioglitazone to prevent intensification of persistent symptoms following cholestyramine treatment of patients with the Post-Lyme Syndrome. (Abst
Ritchie C. Shoemaker2002) Diabetes
Endocrine (ADH/ACTH/MSH)Immune/Innate
Lyme & Co-Infections
Summary
No abstract is available for this paper. It was published in ) Diabetes in 2002 by Ritchie C. Shoemaker. CIRS Nexus tags it under Lyme & Co-Infections, Endocrine (ADH/ACTH/MSH), Immune/Innate.
Part of CIRS Nexus · Curated by Lauren Lowenstein, The Biotoxin Lady
Symptom Clusters
Post-Lyme Syndrome
Related Papers
- Herbal Therapeutics for CIRS Biomarkers in Autism Spectrum Disorders: A Mechanistic and Molecular Approach for Neuroimmune Pathology in PediatricsMedical Research Archives · 2026 · 3 shared tags
- Chronic Fatiguing Illnesses: Entering the era of new biomarkers and therapiesInternal Medicine Review · 2017 · 3 shared tags
- TUBB1, TUBA4A and MAPK as Indicators of Die-Back Degenerative Central Nervous System Disease in Patients Sickened by Specific Exposure to the Interior Environment of Water- Damaged BuildingsMedical Research Archives · 2023 · 3 shared tags
- Autism Spectrum Disorders and Lyme Disease: Exploring Shared Neuro-Inflammatory and Immune PathwaysMedical Research Archives · 2025 · 3 shared tags
- Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical ApplicationsInternational Journal of Molecular Sciences · 2022 · 3 shared tags
- Concurrent Lyme disease and babesiosis: evidence for increased severity and duration of illnessThe Pediatric Infectious Disease Journal · 1997 · 3 shared tags